UDCA administration in patients with gallstones increases expression of MDR3, a phospholipid flippase, in the liver [228] . This might explain the stimulation of biliary phospholipid secretion by UDCA, as described in patients with PSC [246] . Secreted phospholipids form mixed micelles with bile salts, thereby mitigating their toxic effects on cholangiocytes.